Eosinophilic inflammation is a feature of allergic asthma. Despite mounting evidence
showing that chromatin filaments released from neutrophils mediate various diseases, the …

Background This systematic review and meta-analysis aimed to investigate local recurrence
(LR) rates among the three grades (benign, borderline, and malignant) of phyllodes tumors (…

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Activation-induced cell death (AICD) of T lymphocytes can be exploited by cancers to escape
immunological destruction. We demonstrated that tumor-specific cytotoxic T lymphocytes (…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

Understanding molecular mechanisms that dictate B cell diversity is important for targeting
B cells as anti-cancer treatment. Through the single-cell dissection of B cell heterogeneity in …

The leukocyte Fcγ receptor (FcγR)-mediated response is important for the efficacy of therapeutic
antibodies; however, little is known about the role of FcγRs in other cell types. Here we …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

Background A therapeutic vaccine that prevents recurrent tuberculosis would be a major
advance in the development of shorter treatment regimens. We aimed to assess the safety and …